...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>AIDS Research and Human Retroviruses >Efficacy of epoetin alfa administered every 2 weeks to maintain hemoglobin and quality of life in anemic HIV-infected patients.
【24h】

Efficacy of epoetin alfa administered every 2 weeks to maintain hemoglobin and quality of life in anemic HIV-infected patients.

机译：每两周施用一次艾波罗汀的功效，以维持贫血的HIV感染患者的血红蛋白和生活质量。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Anemia, a common hematological abnormality in HIV, contributes to decreased quality of life (QOL). This study assessed once-every-2-week epoetin alfa on maintaining QOL and hemoglobin (Hb) in anemic HIV-infected patients in a 24-week, open-label, multicenter study. HIV-infected patients (Hb < or =12 g/dl) received epoetin alfa 40,000 units subcutaneously once weekly, until reaching Hb > or =13 g/dl. Patients then entered a maintenance phase (MP), in which epoetin alfa was administered every other week or at longer intervals. The trial objectives were to determine if QOL, as measured by the Medical Outcomes Study-HIV (MOS-HIV) general health perceptions (GHP) domain and Hb, was maintained. Safety was also assessed. A total of 292 patients were enrolled (72% on HAART). Mean baseline laboratory values were Hb = 10.8 g/dl, CD4(+) count = 280 cells/microl, and HIV RNA = 51,867 copies/ml. In all, 81% of patients reached Hb > or =13 g/dl and 92% reached Hb > or =12 g/dl. QOL was maintained from the beginning (GHP = 44.2 points) to the end of MP (GHP = 43.4 points) with every other week or longer dosing. Mean Hb at the beginning of MP was 13.4 +/- 0.5 g/dl and was 12.8 +/- 1.4 g/dl at study end. Epoetin alfa was well tolerated; adverse events were consistent with those reported in previous studies of epoetin alfa in HIV-infected patients. Although the clinical approach tested in this study is not consistent with current prescribing recommendations, the results confirm the efficacy of prolonged dosing intervals (every 2-4 weeks) in maintaining optimal Hb levels and QOL in anemic HIV-infected patients.
机译：贫血是艾滋病毒中常见的血液异常，会导致生活质量（QOL）下降。这项研究在一项为期24周的开放标签，多中心研究中评估了每2周一次一次的epoetin alfa在维持贫血的HIV感染者中维持QOL和血红蛋白（Hb）的作用。感染HIV的患者（Hb <或= 12 g / dl）每周皮下接受40,000单位的依泊汀阿尔法，直到达到Hb>或= 13 g / dl。然后，患者进入维持期（MP），其中每隔一周或更长时间间隔服用一次埃泊汀阿尔法。该试验的目的是确定是否维持了QOL（通过医学成果研究-HIV（MOS-HIV）总体健康感知（GHP）域和Hb衡量）。还评估了安全性。共有292例患者入组（HAART率为72％）。平均基线实验室值为Hb = 10.8 g / dl，CD4（+）计数= 280细胞/微升和HIV RNA = 51,867拷贝/毫升。总共有81％的患者血红蛋白≥13 g / dl，而92％的患者血红蛋白≥12 g / dl。从开始（GHP = 44.2点）到MP结束（GHP = 43.4点），每隔一周或更长时间服用一次即可维持QOL。 MP开始时的平均Hb为13.4 +/- 0.5 g / dl，研究结束时为12.8 +/- 1.4 g / dl。埃泊汀的耐受性良好;不良事件与先前对HIV感染患者的依泊汀α的研究报道的事件一致。尽管本研究中测试的临床方法与当前的处方建议不一致，但结果证实了延长剂量间隔（每2-4周）在维持贫血的HIV感染患者中维持最佳Hb水平和QOL的功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号